GASTRIC MICROBIOTA AND POTENTIALS OF PROBIOTICS IN THE ERADICATION OF H. PYLORI


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Gastric microbiota is much more diverse than previously thought; there are 5 predominant major types of microbes among gastric bacterial community: Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria, and Fusobacteria. In patients infected with Helicobacter pylori, there was a significant decrease in the number of bacterial types, especially the number of Bacteroidetes, except for the Proteobacteria. H. pylori creates conditions and certain niches, which are filled with other microbes in the process of progressing atrophy. Reducing microbial diversity may predispose to the development of gastric cancer. A gradual shift in the profile of the gastric microbiota from non-atrophic gastritis to intestinal metaplasia, and then to intestinal type of gastric cancer was observed. Taking into account the possibility of safe and comprehensive impact on the composition of the gastric microbiota, and presence of immunomodulatory effects, probiotics may be promising direction of therapy. Monotherapy with Lactobacillus reuteri (Helinorm) had no significant difference in achieving eradication of H. pylori compared with the standard scheme, but led to a significant decrease in inflammatory changes in the gastric mucosa.

Full Text

Restricted Access

About the authors

E. A Kornienko

St. Petersburg State Pediatric Medical University

Email: e1enkornienk@yandex.ru
MD, Prof., Head of the Department of Gastroenterology

N. I Parolova

St. Petersburg State Pediatric Medical University

References

  1. Sanduleanu S., Jonkers D., De Bruine A., Hameeteman W., Stockbrügger R.W. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment. Pharmacol. Ther. 2001;15:379-88.
  2. Delgado S., Cabrera-Rubio R., Mira A., Suârez A., Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb. Ecol. 2013;65:763-72.
  3. Wang L.L., Yu X.J., Zhan S.H., Jia S.J., Tan Z.B., Dong Q.J. Participation of microbiota in the development of gastric cancer. World J. Gastroenterol. 2014;20(17):4948-52.
  4. Bik E.M., Eckburg P.B., Gill S.R., Nelson K.E., Purdom E.A., Francois F., Perez-Perez G., Blaser M.J., Relman D.A. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl. Acad. Sci. USA. 2006;103:732-37.
  5. Osaki T., Matsuki T., Asahara T., et al. Comparative analysis of gastric bacterial microbiota in Mongolian gerbils after long-term infection with Helicobacter pylori. Microb. Pathog. 2012;53:12-8.
  6. Maldonado-Contreras A., Goldfarb K.C., Godoy-Vitorino F., Karaoz U., Contreras M., Blaser M.J., Brodie E.L., Dominguez-Bello M.G. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME. J. 2011;5:574-79.
  7. Khosravi Y., Dieye Y., Poh B.H., et al. Cuiturabie bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients. Scientif.World J. 2014;610421.
  8. Yeomans N.D., Brimblecombe R.W., Elder J., Heatley R.V., Misiewicz J.J., Northfield T.C., Pottage A. Effects of acid suppression on microbial flora of upper gut. Dig. Dis. Sci. 1995;40:81S-95S.
  9. Sharma B.K., Santana I.A., Wood E.C., Walt R.P., Pereira M., Noone P., Smith P.L., Walters C.L., Pounder R.E. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br. Med. J. (Clin. Res. Ed.) 1984;289:717-19.
  10. Jakszyn P., Bingham S., Pera G., Agudo A., Luben R., Welch A., Boeing H., Del Giudice G., et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric can-cer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis. 2006;27:1497-501.
  11. Calmels S., Ohshima H., Henry Y., Bartsch H. Characterization of bacterial cytochrome cd(1)-nitrite reductase as one enzyme responsible for catalysis of nitrosation of secondary amines. Carcinogenesis. 1996;17:533-36.
  12. Kodama K., Sumii K., Kawano M., Kido T., Nojima K., Sumii M., Haruma K., Yoshihara M., Chayama K. Gastric juice nitrite and vitamin C in patients with gastric cancer and atrophic gastritis: is low acidity solely responsible for cancer risk? Eur. J. Gastroenterol. Hepatol. 2003;15:987-93.
  13. Forsythe S.J., Cole J.A. Nitrite accumulation during anaerobic nitrate reduction by binary suspensions of bacteria isolated from the achlorhydric stomach. J. Gen. Microbiol. 1987;133:1845-49.
  14. Schreiber F., Wunderlin P., Udert K.M., Wells G.F Nitric oxide and nitrous oxide turnover in natural and engineered microbial communities: biological pathways, chemical reactions, and novel technologies. Front. Microbiol. 2012;3:372.
  15. Junier P., Molina V., Dorador C., Hadas O., Kim O.S., Junier T., Witzel J.P., Imhoff J.F. Phylogenetic and functional marker genes to study ammonia-oxidizing microorganisms (AOM) in the environment. Appl. Microbiol. Biotechnol. 2010;85:425-40.
  16. Martin M., Solnick J.V. The gastric microbial community, Helicobacter pylori colonization, and disease. Gut Microbe. 2014;5:345-50.
  17. Rolig A.S., Cech C., Ahler E., Carter J.E., Ottemann K.M. The degree of Helicobacter pylori-triggered inflammation is manipulated by preinfection host microbiota. Infect. Immun. 2013;81:1382-89.
  18. Lofgren J.L., Whary M.T., Ge Z., Muthupalani S., Taylor N.S., Mobley M. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011; 140:210-20
  19. Lee C.W., Rickman B., Rogers A.B., Muthupalani S., Takaishi S., Yang P., Wang T.C., Fox J.G. Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 2009;69: 8166-74.
  20. Yu G., Gail M.H., Shi J., Klepac-Ceraj V., Paster B.J., Dye B.A., Wang G.Q., Wei W.Q., Fan J.H., Qiao Y.L., Dawsey S.M., Freedman N.D., Abnet C.C. Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach. Cancer Epidemiol. Biomarkers Prev. 2014;23(5):735-41.
  21. Dicksved J., Lindberg M., Rosenquist M., Enroth H., Jansson J.K., Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J. Med. Microbiol. 2009;58(Pt. 4):509-16.
  22. Aviles-Jimenez F., Vazquez-Jimenez F., Medrano-Guzman R., Mantilla A., Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci. Rep. 2014;4:4202.
  23. Yang I., Woltemate S., Piazuelo M.B., Bravo L.E., Yepez M.C., Romero-Gallo J., Delgado A.G., Wilson KT, Peek R.M., Correa P., Josenhans C., Fox J.G., Suerbaum S. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci. Rep. 2016;6:18594.
  24. Midolo P.D., Lambert J.R., Hull R., Luo F., Grayson M.L. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J. Appl. Bacteriol. 1995;79:475-79.
  25. Aiba Y., Suzuki N., Kabir A.M., Takagi A., Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic model. Am. J. Gastroenterol. 1998;93:2097-101.
  26. Kim T.S., Hur J.W., Yu M.A., Cheigh C.I., Kim K.N., Hwang J.K., Pyun Y.R. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J. Food Prot. 2003;66:3-12.
  27. Lorca G.L., Wadstrom T., Valdez G.F., Ljungh A. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr. Microbiol. 2001;42:39-44.
  28. Michetti P., Dorta G., Wiesel P.H., Brassart D., Verdu E., Herranz M., Felley C., Porta N., Rouvet M., Blum A.L., Corthésy-Theulaz I. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion. 1999; 60:203-9.
  29. Coconnier M.H., Lievin V., Hemery E., Servin A.L. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl. Environ. Microbiol. 1998;64:4573-80.
  30. Uchida M., Kurakazu K. Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against acute gastric lesion and antral ulcer in rats. J. Pharmacol. Sci. 2004;96:84-90.
  31. Nagaoka M., Hasimoto S., Watanabe T, Yokokura T., Mori Y. Anti-ulcer effects of lactic acid bacteria and their cell wall polysaccharides. Biol. Pharm. Bull. 1994;17:1012-17.
  32. Cindoruk M., Erkan G., Karakan T., Dursun A., Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double blind stude. Helicobacter. 2007;12(4):309-16.
  33. Duman D.G., Bor S., Ozutemiz O., et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated Diarrhoea due to Helicobacter pylori eradication. Eur. J. Gastroenterol. Hepatol. 2005;17:1357-61.
  34. Lionetti E., Miniello V.L., Castellaneta S.P., Magista A.M., De Canio A., Giovanni M., Ierardi E., Cavallo L., Francavilla R. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment. Pharmacol. Ther. 2006;24:1461-68.
  35. Корниенко Е.А. Инфекция Helicobacter pylori у детей. М., 2011. 272 с.
  36. Sheu B.S., Cheng H.C., Kao A.W., Wang S.T., Wang S.T., Yang Y.J., Yang H.B., Wu J.J., et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am. J. Clin. Nutr. 2006; 83:864-69.
  37. Sykora J., Valeckova K., Amlerova J., Siala K., Dedek P., Watkins S., Varvarovskâ J., Stozicky F., Pazdiora P., Schwarz J. Effect of specially designed fermented milk product containing probiotic Lactobacillus casei DN-114001 and the eradication of H.pylori in children. J. Clin. Gastroenterol. 2005;39:692-98.
  38. Uemura N. H.pylori infection and high risk of gastric cancer - Is improvement of atrophic gastritis by probiotics LG21 possible? Abstracts of the 6 Western Pacific Helicobacter congress, 2006, Bangkok. Р 73.
  39. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and metaanalysis of randomized-controlled trials. Eur. J. Gastroenterol. Hepatol. 2009;21(1):45-53.
  40. Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus in children colonised by Helicobacter pylori. Acta Paediatr. 2005;94:1747-51.
  41. Симаненков В.И., Суворов А.Н. Роль пробиотиков в проблеме эрадикации H. pylori. В кн: Дисбиоз кишечника / Под ред. Е.И. Ткаченко, А.Н. Суворова, СПб., 2007. с. 108-14.
  42. Pantoflickova D., Corthesy-Theulaz I., Dorta G., Stolte M., Isler P., Rochat F., Enslen M., Blum A.L. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment. Pharmacol. Ther. 2003;18:805-13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies